explore -WSS

explore

author：comprehensive 2025-09-27 10:04:29 - browse：68

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

WSS

Parkinson’s finding may lead to tests and, someday, treatments

Test for long Covid? Researchers find new clue in blood samples

How digital therapeutics firms are pivoting after Pear's bankruptcy

Medical device lobby: We're tired of waiting on Medicare coverage

New brain studies show LSD's effects on the brain in full color

House looks to weaken Medicare negotiation

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Biotech companies concerned about China biosecurity crackdown

Medicare proposal to cover medical devices draws a mixed reaction

FDA clears AI tool for detecting skin cancer

Cancer drug shortages should be causing more outrage

How digital therapeutics firms are pivoting after Pear's bankruptcy

Anesthesiologist group: stop taking Ozempic before surgery

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Medicare proposal to cover medical devices draws a mixed reaction

International team creates first chimeric human

leisure time

The tragedy of Johnson & Johnson’s Covid vaccine

Why doctors need education on FDA device approval process

Why getting cancer drugs just got harder for rural patients

How digital therapeutics firms are pivoting after Pear's bankruptcy

FDA clears AI tool for detecting skin cancer

Why doctors need education on FDA device approval process

focus

knowledge

leisure time

entertainment